Trillium is hunting giants with its anti-CD47 drug, but questions over a high-dose solo regimen still linger
CD47 player Trillium Therapeutics released a new slate of data for two of its experimental cancer drugs on Wednesday, updating previously released results from last winter’s ASH conference. But even though higher doses of the programs were administered since then, the overall response rates stayed roughly the same.
As of the new April 12 data cutoff for the lead TTI-622 program, 9 of 27 evaluable patients with relapsed or refractory lymphoma recorded an objective response, good for a 33% ORR. That rate fell slightly from the ASH data cutoff, where 6 of 17 evaluable patients saw responses, or 35%. One new complete response and two new partial responses were observed at the two highest doses since the ASH update, Trillium said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
